Another point to mention is that PHH3 staining has the same cost as other routinely assessed IHC markers in BC such as ER and Her2, and can provide prognostic value at a lower cost than existing multigene assays and will refine BC grading when using WSIs, which are associated with lower mitoses detection ability48; it has been shown to be more time‐consuming than counting using conventional microscopes.49 This evidence concerns the gene ERBB2 and breast cancer.